SQZ Biotechnologies Company
SQZ Biotechnologies Company
Your view on SQZB
Overview
What the company does, where it operates, and who runs it.
About SQZ Biotechnologies Company
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lawrence J. Knopf
- Headquarters
- 200 Arsenal Yards Boulevard, Watertown, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Lawrence J. Knopf
- Headquarters
- 200 Arsenal Yards Boulevard, Watertown, MA, US
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions.
Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer.
The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers.
The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SQZ Biotechnologies Company, and the rating behind it. SQZB last traded at $0.02; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SQZ Biotechnologies Company. Starting points for SQZ Biotechnologies Company: EPS -$2.76, beta 0.32 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SQZ Biotechnologies Company. SQZ Biotechnologies Company does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SQZ Biotechnologies Company. Trailing twelve-month EPS for SQZ Biotechnologies Company stands at -$2.76. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SQZ Biotechnologies Company. SQZ Biotechnologies Company has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SQZ Biotechnologies Company valued side by side against its closest peers. SQZ Biotechnologies Company is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SQZ Biotechnologies Company, and how their positions are changing. At a $707,787 market value, institutional positions materially move SQZ Biotechnologies Company's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SQZ Biotechnologies Company executives and directors. Shares of SQZ Biotechnologies Company have traded between $0.02 and $0.07 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SQZ Biotechnologies Company. SQZ Biotechnologies Company is a $707,787 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SQZ Biotechnologies Company. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SQZ Biotechnologies Company. Coverage tracks SQZ Biotechnologies Company within Biotechnology (Healthcare). Press releases and market coverage, newest first.